Responses of growth hormone (GH) release to synthetic human growth hormone-releasing factor (hGRF)-44-NH2 analogs were determined, and the GH-releasing potency based on dose per kg of body weight (bw) was compared with that of hGRF-44-NH2 in female dairy calves. Four-and 12-month-old calves were injected intravenously with 0.25pg of hGRF-44-NH2 or its analogs per kg of bw. Blood samples were collected before, and during 180min after each injection, and plasma GH concentrations were measured by radioimmunoassay. Areas under the GH response curves for 180min after injection of hGRF-44-NH2 and its analogs were used as an index of the GH-releasing potency of each peptide. The GH-releasing potency of hGRF(1-26)-NH2 was significantly lower than that of hGRF-44-NH2 (P<0.05).
Recently, growth hormone-releasing factors (GRFs) have been isolated, purified and characterized (Guillemin et al., 1984) . Synthetic human GRF (hGRF)-44-NH 2 specifically stimulates the release of growth hormone (GH) in humans (Guillemin et al., 1984) , rats (Guillemin et al., 1984) , rabbits (Chihara et al., 1984) , chickens (Leung and Taylor, 1983; Harvey and Scanes, 1984) , goats (Hodate et al., 1984 (Hodate et al., , 1985a Hart et al., 1984) , sheep (Hodate et al., 1985a) , cattle (Hodate et al., 1984; Johke et al., 1984; Moseley et al., 1984) and pigs (Hodate et al., 1985b) . To elucidate the structureactivity relationships of GRFs, the relative GH-releasing potencies of several kinds of analogs or fragments of hGRF-44-NH2 have been studied mainly in the rat (Guillemin et al., 1984; Rivier et al., 1982; Wehrenberg and Ling, 1983; Ling et al., 1984; Ohashi et al., 1984; Lance et al., 1984; Heiman et al., 1985) and also in domestic animals (Hodate et al., 1985c; Lance et al., 1984; McCutcheon et al., 1984) . In the rat, Rivier et al. (1982) found that hGRF (1-29)-NH2 has full intrinsic GH-releasing potency in vitro. Lance et al. (1984) reported that [D-Ala2]-hGRF(1-29)-NH2 was approximately 50 times more potent than hGRF(1-29)-NH2 in eliciting GH secretion in vivo. The GH responses to hGRF(1-29)-NH2 in lactating cows (McCutcheon et al., 1984) and pigs Kraft et al., 1985) and to [D-Ala2]-hGRF(1-29)-NH2 in pigs have been also determined. However, the relative GHreleasing potencies of these peptides to hGRF-44-NH2 are not known in the farm animals.
In the present experiments, we studied the GH-releasing potencies of hGRF(1-29)- The animals were fed at 0830 h, and synthetic hGRF-44-NH2, its analogs, or saline were given at 1100 h.
Preparations of synthetic hGRF-44-NH2 and its analogs for injection
The hGRF-44-NH2 and its analogs: hGRF (1-26)-NH2 and hGRF(1-29)-NH2, fragments with 18 and 15 amino acids deleted from the Cterminal of hGRF-44-NH2 respectively; [D-Tyr1]-hGRF-44-NH2, an analog with D-Tyr substitution in N-terminal Tyr of hGRF-44-NH2; [DAla9-hGRF(1-29)-NH2, an analog with D-Ala substitution in position-2 Ala of hGRF(1-29)-NH2, were synthesized by the solid-phase method and purified by HPLC . These preparations were dissolved in 3 ml of sterilized saline before use and injected intravenously (iv) through an indwelling catheter inserted into one of the external jugular veins. The concentrations of plasma GH were determined by radioimmunoassay (Johke, 1978) . Areas under the GH response curves for 180min after each injection were determined and regarded as the total amount of GH released in response to hGRF-44-NH2, its analogs, or saline. These areas under the GH response curves were used as an index of the GH-releasing potency of each peptide.
The paired t-test was used to assess the significance of the differences in the data (Snedecor and Cochran, 1980 -30, -15, 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150 , and 180min after injection. In another group (322kg mean bw), 3ml saline (as a control) was injected iv into each of the four calves. The blood samples were drawn at 15-min intervals. The experiments were carried out between late November and early December, and treatments were carried out a 1-week intervals.
Results

GH responses to hGRF-44-NH2, hGRF(1-26)-NH2, and [D-Tyr1]-hGRF-44-NH2
The responses of plasma GH in the 4-month-old calves to a single injection of 
Discussion
Our results demonstrate that an analog with D-Ala substitution in position-2 Ala of hGRF(1-29)-NH2, [D-Ala2]-hGRF(1-29)-NH2, exhibits the prolongation of GHreleasing activity and a significant increase in potency based on dose per kg of bw compared with that of hGRF-44-NH2 or hGRF(1-29)-NH2 in the 12-month-old calves. Similar phenomena were also observed in the lactating cows (Johke et al., unpublished data) and goats (Hodate et al., unpublished data) . In the rat, this analog was approximately 50 times more potent than hGRF(1-29)-NH2 in eliciting GH secretion both in vivo and in vitro (Heiman et al., 1985 showed prolonged GH-releasing activity compared with hGRF-44-NH2 in the 4-month-old calves, its potency was similar to that of hGRF-44-NH2. This result agreed with the in vivo result reported previously in 10-month-old calves or wethers (Hodate et al., 1985c) and the in vitro result in the rat .
Our results also demonstrate that deletion of 18 amino acids from the C-terminal of hGRF-44-NH2 causes a significant decrease in the in vivo GH-releasing potency in calves, but deletion of 15 amino acids does not reduce the potency. In the rat, deletion of as many as 13 amino acids failed to reduce the in vivo GH-releasing activity; however, deletion of 16 amino acids resulted in a significant decrease (Wehrenberg and Ling, 1983) . Moreover, it has been reported that hGRF(1-29)-NH2 is approximately one half as potent as hGRF(1-40)-OH in the in vivo assay in the rat , but has similar potency to hGRF(1-40)-OH when tested in vitro with rat pituitary cell cultures (Rivier et al., 1982) . In a previous study, we suggested that the amino acid residues above 27 from the N-terminal of hGRF-44-NH2 are essential for exerting sufficient GRF activity in vivo in cattle and sheep (Hodate et al., 1985c) . The present results support the above findings, and suggest that the N-terminal 29 amino acid residues of hGRF possess the activity site required for full bovine GH release in vivo.
In previous studies, the responses of GH release to hGRF-44-NH2 in cattle (Johke et al., 1984) , goats (Hodate et al., 1985a) and sheep (Hodate et al., 1985a) have been shown to decrease with advancing age. Both the peak level of plasma GH and the area under the GH response curve for 180min after injection of hGRF-44-NH2 in the 4-month-old calves tended to be larger than in the 12-month-old calves, though the differences were not statistically significant in the present experiments. In cattle, it has been reported that the basal GH level and peak level of plasma GH after injection of thyrotropin releasing hormone did not differ significantly between May and October (Johke, 1978) . Therefore, the response of bovine GH release to hGRF-44-NH2 may not be affected by the season.
We conclude that, on the basis of the dose per kg of bw, the in vivo GH-releasing potency of hGRF(1-29)-NH2 is equal to that of hGRF-44-NH2, and [D-Ala2]-hGRF(1-29)-NH2 has longer and greater activity than hGRF-44-NH2 or hGRF(1-29)-NH2 in stimulating GH release in calves.
